A Study to Evaluate the Safety and Immunogenicity of IVX-A12 in Participants of 60 to 85 Years of Age

Healthy Clinical Trial

Official title:

A Phase 2a Randomized, Observer-blind, Placebo-controlled, Dosage Optimization, Multi-center Clinical Trial to Evaluate the Safety and Immunogenicity of IVX-A12, a Respiratory Syncytial Virus and Human Metapneumovirus Bivalent Combination Virus-like Particle Protein Subunit Vaccine, in Adults 60 to 85 Years of Age

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05903183
• Other study ID #: ICVX-12-201
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: May 15, 2023
• Est. completion date: September 30, 2025

Study information

• Verified date: March 2024
• Source: Icosavax, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary purpose of the study is to assess the safety, tolerability and immunogenicity of a bivalent respiratory syncytial virus (RSV)/human metapneumovirus (hMPV) virus-like particle (VLP) candidate vaccine (IVX-A12) compared to placebo, when administered as a single-dose regimen in healthy older adults 60 to 85 years of age.

Description:

The IVX-A12 Phase 2a clinical trial is a randomized, observer-blind, placebo-controlled, dosage optimization, multi-center trial to evaluate the safety and immunogenicity of a single intramuscular (IM) dose of IVX-A12, with or without adjuvant, in adults 60 to 85 years of age. Participants will be administered a single shot of IVX-A12, at specified dosage levels, or placebo. The overall duration of the study is up to 1 year (12 months). A subset of participants will be followed for an additional 12 months for a total duration of 24 months.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 264
• Est. completion date: September 30, 2025
• Est. primary completion date: July 5, 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 60 Years to 85 Years

Eligibility

Inclusion Criteria:

1. Male or female participants, who must be in stable health based on medical history, vital signs, physical examination, and laboratory evaluation prior to vaccination, in the investigator's clinical judgment

2. Participants may have ongoing chronic conditions (comorbidities such as hypertension, congestive heart failure, chronic obstructive pulmonary disease, type 2 diabetes mellitus, hyperlipoproteinemia, or hypothyroidism) who are, in the investigator's opinion, medically compensated and without recent exacerbation within the prior 3 months

3. Participants able to voluntarily give written informed consent and can comply with trial procedures including follow-up for approximately 12 months after vaccination

4. Body mass index 17 to less than (<) 40 kilograms per square meter (kg/m^2) at screening

5. Before randomization, female participants must be unable to conceive (example, menopausal, that is, 12 consecutive months without menstruation, hysterectomy, oophorectomy, etc.) and not intending to conceive by any method

6. Participants must agree not to donate blood from the time of vaccination through 3 months after vaccination

7. Participants must be willing to provide verifiable identification and have the means to be contacted and to contact the investigator or the site's staff during the entire clinical trial

Exclusion Criteria:

1. Participants with moderate or severe liver disease, metastatic solid tumor, and acquired immunodeficiency syndrome (AIDS) are to be excluded. In addition, participants with underlying significant illness or condition(s) or ongoing treatment that, in the opinion of the investigator, could (i) interfere with the conduct of the trial, (ii) pose an unacceptable risk to the participant in this trial, (iii) interfere with the participant's ability to comply with the trial procedures or abide by the procedures

2. Older adults who meet frail elderly criteria (older persons with medical, nutritional, cognitive, emotional, or activity impairments, as defined by the Dalhousie Clinical Frailty Score greater than or equal to [>=]4)

3. Prior receipt of any licensed or investigational RSV or hMPV vaccine within the past 12 months

4. Prior receipt of another investigational medicinal product (IMP; trial drug, biologic, or device) not authorized for use in the United States of America (USA) and European Union within the past 3 months

5. Laboratory-confirmed RSV or hMPV infection within 12 months prior to enrollment

6. Currently enrolled or plan to participate in another clinical trial with an investigational agent (including licensed or unlicensed vaccine, drug, biologic, device, blood product, or medication) to be received during the trial period

7. History of malignancy within 5 years before screening not in the following categories:

(i) participants with squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix may be enrolled at the discretion of the investigator, (ii) participants with a history of malignancy within 5 years before screening, with minimal risk of recurrence per investigator's judgment, can be enrolled

8. Acute illness, with or without fever at the time of planned vaccination

9. History of hypersensitivity or serious adverse reactions to vaccines, such as anaphylaxis or angioedema, or any known allergies to any component of the IVX-121 and/or IVX-241 vaccine, or hypersensitivity to latex

10. Abnormal function of the immune system resulting from clinical conditions including chronic administration of systemic corticosteroids (oral/intravenous/IM at a daily dose equivalent of greater than (>) 20 milligram (mg) prednisone in a period of more than 14 days), or administration of immunosuppressive chemotherapy, biologics, or radiotherapy within the past 3 months prior to planned vaccination

11. Participants who have received treatment with immunoglobulins or other biologics, such as immunosuppressive therapies expected to modify immune response to vaccination (including monoclonal antibodies [MAbs] for chronic underlying conditions) within the past 3 months prior to planned vaccination

12. Trial personnel as an immediate family or household member

13. For licensed vaccines:

1. Receipt of licensed inactivated vaccines (including seasonal influenza vaccine) within 14 days prior to trial vaccine administration on Day 0, or licensed replicating vaccines such as ribonucleic acid (RNA) or live-attenuated virus vaccines within 30 days prior to Day 0

2. Receipt of licensed vaccines is permitted after completion of the Day 28 visit

3. Receipt of any licensed Coronavirus Disease-2019 (COVID-19) vaccines is permitted if dosing regimen completed within 21 days prior to Day 0 or after completion of the Day 28 visit.

Related Conditions & MeSH terms

• Healthy

Intervention

Biological:
• IVX-A12
IVX-A12 without adjuvant
• IVX-A12
IVX-A12 with adjuvant
• Placebo
Diluent

Locations

Country	Name	City	State
United States	PanAmerican Clinical Research	Brownsville	Texas
United States	Cenexel RCA	Hollywood	Florida
United States	Johnson City Clin-Trials (JCCT)	Lenexa	Kansas
United States	AMR Lexington	Lexington	Kentucky
United States	Velocity Clinical Research-Boise	Meridian	Idaho
United States	ASR, LLC	Nampa	Idaho
United States	Velocity Clinical Research	Omaha	Nebraska
United States	Rochester Clinical Research, Inc	Rochester	New York
United States	Clinical Research Atlanta	Stockbridge	Georgia
United States	AMR Phoenix	Tempe	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
Icosavax, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Solicited Local Reactions and Systemic Adverse Events (AEs)		From Day 0 to Day 6
Primary	Number of Participants With Unsolicited AEs		From Day 0 to Day 28
Primary	Geometric Mean Titers (GMT) for RSV/A, RSV/B, hMPV/A, and hMPV/B-specific Neutralizing Antibodies (NAb)		At Day 28
Primary	GMT for RSV and hMPV Prefusion F protein-specific IgG Antibodies	RSV and hMPV Prefusion F protein-specific IgG Antibody Titers will be measured by enzyme-linked immunosorbent assays (ELISAs).	At Day 28
Primary	Percentage of Participants With a >=4-fold Increase in Serum anti-RSV/A, RSV/B, hMPV/A, and hMPV/B-specific NAb		From Day 0 (pre-vaccination) up to Day 28 post-vaccination
Primary	Percentage of Participants with >=4-fold Increase in RSV and hMPV-specific IgG Antibody Titers		From Day 0 (pre-vaccination) up to Day 28 post-vaccination
Primary	Geometric Mean Fold Rise (GMFR) in Serum for Anti-RSV/A, RSV/B, hMPV/A, and hMPV/B-Specific NAb titers	GMFR is defined as the geometric mean of the ratio of concentration of antibodies at specified timepoints after vaccination divided by concentration at baseline (Day 0).	From Day 0 (pre-vaccination) up to Day 28 post-vaccination
Primary	Geometric Mean Fold Rise (GMFR) in Serum for RSV and hMPV Prefusion F Protein-specific IgG Antibodies	GMFR is defined as the geometric mean of the ratio of concentration of antibodies at specified timepoints after vaccination divided by concentration at baseline (Day 0).	From Day 0 (pre-vaccination) up to Day 28 post-vaccination
Secondary	Number of Participants With Serious Adverse Event (SAE), Medically-attended Adverse Events (MAAEs), and AEs Leading to Trial Withdrawal		From Day 0 up to the end of study (up to Day 365)
Secondary	Number of Participants With Mild, Moderate, or Severe Lower Respiratory Tract Illness (LRTI) Caused by RSV and/or hMPV		From Day 0 up to the end of study (up to Day 365)
Secondary	Number of Participants With Clinically Significant Safety Laboratory Parameters		At Screening, Days 0, 7 and 28
Secondary	Number of Participants With Mild, Moderate, or Severe LRTI Cases not Caused by RSV or hMPV		From Day 0 up to the end of study (up to Day 365)
Secondary	GMTs for RSV/A, RSV/B, hMPV/A, and hMPV/B-specific NAb		At Days 0, 180, and 365
Secondary	GMTs for RSV and hMPV Prefusion F Protein-specific IgG Antibody Titers	RSV and hMPV Prefusion F protein-specific IgG Antibody Titers will be measured by ELISA.	At Days 0, 180, and 365
Secondary	Percentage of Participants With a >=4-fold Increase in Serum Anti-RSV/A, RSV/B hMPV/A, and hMPV/B-specific NAb		From Day 0 (pre-vaccination) up to Days 180, and 365 post-vaccination
Secondary	Percentage of Participants With a >=8-fold Increase in Serum anti-RSV/A, RSV/B, hMPV/A, and hMPV/B-specific NAb		From Day 0 (pre-vaccination) up to Days 28, 180, and 365 post-vaccination
Secondary	Percentage of Participants With >=4-fold increase in RSV and hMPV prefusion F Protein-specific IgG Antibody Titers		From Day 0 (pre-vaccination) up to Days 180, and 365 post-vaccination
Secondary	GMFR in Serum for Anti-RSV/A, RSV/B, hMPV/A, and hMPV/B-specific NAb and RSV and hMPV Prefusion F Protein-specific IgG Antibodies	GMFR is defined as the geometric mean of the ratio of concentration of antibodies at specified timepoints after vaccination divided by concentration at baseline (Day 0).	From Day 0 (pre-vaccination) up to Days 180 and 365 post-vaccination
Secondary	Reverse Cumulative Distribution (RCD) Curve of Serum NAb and IgG Antibody Titers	Distribution of Serum NAb and IgG antibody titers displayed as reverse cumulative distribution curve at Days 0, 28, 180, and 365 post-vaccination will be reported.	At Days 0, 28, 180, and 365 post-vaccination